Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
… in the study ( table 1): 61 from the Royal Free (RFH), 50 from University College of London (UCLH), and 24 from North Middlesex (NMH) hospital.49/135 (36%)…
…ase and impact on patients’ lives. Nalbuphine extended-release (NAL ER, oral tablet form) is a kappa receptor agonist and mu receptor …
…ducted on 38 patients with 41 lung lesions (n=41) who underwent Tektrotyd SPECT between March 2012 and April 2023 for suspected lung NENs…
…ted for potential confounders.Results 13,710 patients following influenza, 42.5% male, median age 57.6 (range 18 to 103) had a DM inciden…
…Conclusions In patients with type 2, moderate-to-severe asthma, dupilumab significantly increased spirometry-derived ratios, indicating i…
…us (EUS-B-FNA). A meta-analysis involving lymph node staging of lung cancer demonstrated a higher diagnostic yield of EUS-B-FNA in combinat…
…h STOP-BANG <3.Conclusion In this female-predominant, difficult asthma cohort, STOP-BANG ≥3 showed modest sensitivity and limited spec…
… chance of successful implementation of anti-inflammatory-based asthma management.…
…%, 13.5%); weighted prevalence was 13.4% (95% CI 11.1%, 16.0%). Silicosis prevalence among ex-miners was 31/86, (36.0%, 95% CI 25.9%, 46.…
…adapted to meet PRSAS standards, on outcomes in patients from a COPD community service (CCS), compared to the former PR programme (P…
…es are shown in bold where p<0.05.Conclusion Patients receiving mepolizumab achieve early responses with significant overall symptom VAS an…
…thelial and endothelial barrier, resulting in pulmonary oedema. Baricitinib is a JAK1/2 inhibitor which inhibits inflammation in experiment…